Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

Abstract

Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2018-06-26T17:42:52Z No. of bitstreams: 1 Carneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf: 706114 bytes, checksum: b9212b392b344bad0398cdf571f61ce6 (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2018-06-26T17:55:09Z (GMT) No. of bitstreams: 1 Carneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf: 706114 bytes, checksum: b9212b392b344bad0398cdf571f61ce6 (MD5)Made available in DSpace on 2018-06-26T17:55:09Z (GMT). No. of bitstreams: 1 Carneiro Neto JA Onabotulinumtoxin type A improves lower ......pdf: 706114 bytes, checksum: b9212b392b344bad0398cdf571f61ce6 (MD5) Previous issue date: 2018Universidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / Universidade Estadual de Feira de Santana. Feira de Santana, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Imunologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Pós-Graduação em Ciências da Saúde. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Urologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Urologia. Salvador, BA, BrasilUniversidade Federal da Bahia. Hospital Universitário Prof. Edgard Santos. Serviço de Urologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica. Salvador, BA, Brasil / Instituto Nacional de Ciência e Tecnologia de Doenc¸as Tropicais. Salvador, BA, BrasilTo evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). Methods: Case series with 10 patients with overactive bladder refractory to conservativetreatment with anticholinergic or physical therapy. They received 200Ui of onabotulinum-toxin type A intravesically and were evaluated by overactive bladder symptoms score(OABSS) and King’s Health Questionnaire.Results: The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them hadconfirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. Themedian and range of the OABSS was 13 (12–15) before therapy and decreased to 1.0 (0–12)on day 30 and to 03 (0–14) on day 90 (p < 0.0001). There was a significant improvement in 8 ofthe 9 domains of the King’s Health Questionnaire after the intervention. Hematuria, urinaryretention and urinary infection were the complications observed in 3 out of 10 patients. Themean time to request retreatment was 465 days.Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effectand improved the quality of life of HTLV-1 infected patients with severe overactive bladder

    Similar works

    Full text

    thumbnail-image